Vischer and Walder Wyss on Oculis Series C financing round
Oculis has closed an oversubscribed USD 57m Series C financing round.
It was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Capital Management, Pivotal bioVenture Partners, Nan Fung Life Sciences, Novartis Venture Fund, Silfurberg, as well as other existing investors. This excellent syndication further broadens Oculis’ strong shareholder base of leading life sciences investors from the US, China and Europe.
Proceeds from this financing will accelerate Oculis’ strategy with the aim of delivering key goals in the near-term to drive shareholder value and bring transformative therapies to patients.
Vischer advised Oculis with a team led by Matthias Staehelin (pictured – Partner) and comprising Vincent Reardon (managing associate).
Walder Wyss advised Hyfinity Investments with a team that included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) and Karina Tschon (Associate, Corporate/M&A and Venture Capital).
Oculis is a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients.
